Table 2.
Anti-arrhythmic Effects of Flecainide and Tetracaine in Ventricular Myocytes and Purkinje Cells
| Cells with SCaEs | SCaEs Per Cell | |||
|---|---|---|---|---|
| CON | FLEC | CON | FLEC | |
| WT VM | 14% (28) | 3% (36) | .18 ± .09 (28) | .03 ± .03 (36) |
| WT PC | 45% (20) | 11% (18) | .80 ± .24 (20) | .22 ± .17 (18) |
| MUT VM | 43% (56) | 34% (71) | .68 ± .13 (56) | .61 ± .12 (71) |
| MUT PC | 76% (25) | 27% (37) | 2.64 ± .47 (25) | .57 ± .19 (37) |
| CON | TETR | CON | TETR | |
| MUT VM | 54% (24) | 16% (25) | .79 (24) | .16 (25) |
| MUT PC | 89% (19) | 27% (11) | 3.58 (19) | .73 (11) |
Data are shown as percentage of of cells with spontaneous Ca2+ release events (SCaEs) and the mean ± SEM SCaEs/cell. The number of cells studied for each condition are shown in parentheses.WT, wild type; MUT, mutant; VM, ventricular myocyte; PC, Purkinje cell.